top of page
Contact Us

Overview of Building 66 at the FDA White Oak Campus


Introduction to Building 66 at the FDA


Building 66, located at the FDA White Oak Campus in Silver Spring, Maryland, is a pivotal facility for the U.S. Food and Drug Administration (FDA). It houses the Center for Devices and Radiological Health (CDRH). This building is part of a larger campus that embodies the FDA's commitment to operational excellence and scientific advancement in public health.


Development of the White Oak Campus


The FDA White Oak Campus was established following the FDA Revitalization Act of 1990, aimed at consolidating various FDA operations into a single location to enhance efficiency and collaboration. The campus encompasses ten office buildings and four laboratory buildings, totaling approximately 3.1 million rentable square feet. Building 66 was officially dedicated on May 11, 2009, marking a significant milestone in the FDA's efforts to modernize its facilities and improve its regulatory capabilities.


Legislative Framework


Various legislative acts have supported the construction and expansion of the White Oak Campus, including the Family Smoking Prevention and Tobacco Control Act of 2009, FDA Food Safety Modernization Act of 2011, FDA Safety and Innovation Act of 2012, Drug Quality and Security Act of 2013, 21st Century Cures Act of 2016, and FDA Reauthorization Act of 2017.


Design and Structure


Building 66 is designed to facilitate the work of CDRH, which ensures that medical devices and radiological health products are safe and effective. The building has been recognized for its sustainable design practices, earning LEED certification from the U.S. Green Building Council, indicating it meets high standards for energy efficiency and environmental sustainability.

The interior layout is optimized for administrative functions and scientific research, featuring state-of-the-art laboratories for testing and evaluating medical devices, office spaces designed to foster communication and collaboration, and meeting rooms for discussions, presentations, and training sessions. Recent renovations included an accessible walkway connecting Building 10 to Building 66 with a climate-controlled vestibule.


Mission and Responsibilities


The CDRH protects public health by regulating medical devices and ensuring their safety and effectiveness. Key responsibilities include pre-market review of new medical devices before they can be marketed, post-market surveillance to monitor devices after they reach the market, and guidance development to help manufacturers comply with regulatory standards.


Research Initiatives


The CDRH engages in various research initiatives aimed at improving device safety, including clinical studies collaborating with manufacturers to assess device performance, public health research investigating trends in device-related injuries or complications, and innovation support providing resources for emerging technologies in medical devices.


Visitor Access and Outreach


Building 66 is accessible to visitors who wish to learn more about the FDA's work. The campus offers guided tours highlighting its facilities and educational resources, and the FDA conducts outreach programs to educate healthcare professionals about regulatory processes related to medical devices.


Expansion Plans


As part of ongoing efforts to meet increasing demands for regulatory oversight, there are plans for further expansion of the White Oak Campus. The National Capital Planning Commission approved a Master Plan in December 2018 that outlines these future developments.


References

Beyond The Page

Expertise in Every Niche.

Congratulations to Brendan Keenan and Greg Maislin for their recent publication on Propensity Score designs!

In the article, the authors propose that Propensity Score designs are the optimal approach to address the impact of continuous positive airway pressure (CPAP) on cardiovascular events.

Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!

The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion. 

Congratulations to David Maislin and Brendan Keenan on their article in collaboration with UPenn!

This article cover the effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling in Non-Obese and Obese Adults.

WHAT CLIENTS SAY

“They listen the first time. I’ve never had to go back and respell out what I needed." 


”They work to understand the problem and leverage the information that is already there.”

Former FDA Regulator

WHAT CLIENTS SAY

"Battle ground tested."


"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”

Vice President, Clinical Operations

WHAT CLIENTS SAY

"Get stuff done when you have to do something no one else has done before."


"They aren’t afraid to tackle difficult scenarios in compressed timelines."

CEO, Medical Device Company

BSC® Differentiator

What Sets us Apart

Submission Grade Experience

Regulatory-first biostatistics

Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.

Direct communication, faster turn around

Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.

Versatile Solutions

Engage us for a focused analysis or a full submission, We size the work to the problem.

Proven FDA Experience

Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.

bottom of page